1.Pelvic Hydatidosis Mimicking a Malignant Multicystic Ovarian Tumor.
Prem SING ; Deeba MUSHTAQ ; Neetu VERMA ; N C MAHAJAN
The Korean Journal of Parasitology 2010;48(3):263-265
Echinococcosis is a multisystem disease and has propensity to involve any organ, an unusual anatomical site, and can mimic any disease process. Primary peritoneal echinococcosis is known to occur secondary to hepatic involvement but occasional cases of primary peritoneal hydatid disease including pelvic involvement have also been reported. We report here 1 such case of primary pelvic hydatidosis mimicking a malignant multicystic ovarian tumor where there was no evidence of involvement of the liver or spleen. Our patient, a 27-year-old female, was detected to have a large right cystic adnexal mass on per vaginal examination which was confirmed by ultrasonography. Her biochemical parameters were normal and CA-125 levels, though mildly raised, were below the cut off point. She underwent surgery and on exploratory laparotomy, another cystic mass was found attached to the mesentery of the small gut. The resected cysts were processed histopathologically. On cut sections both large cysts revealed numerous daughter cysts. Microscopic examination of fluid from the cysts revealed free scolices with hooklets and the cyst wall had a typical laminated membrane with inner germinal layer containing degenerated protoplasmic mass. The diagnosis of pelvic hydatid disease was confirmed and patient was managed accordingly. Hydatid disease must be considered while making the differential diagnosis of pelvic cystic masses, especially in endemic areas.
Adult
;
Animals
;
Echinococcosis/diagnosis/*parasitology
;
Echinococcus granulosus/*isolation & purification
;
Female
;
Humans
;
Ovarian Cysts/diagnosis/*parasitology
;
Ovarian Neoplasms/diagnosis/*parasitology
;
Pelvic Infection/diagnosis/*parasitology
2.Colitis and Crohn’s Foundation (India): a first nationwide inflammatory bowel disease registry
Ajit SOOD ; Kirandeep KAUR ; Ramit MAHAJAN ; Vandana MIDHA ; Arshdeep SINGH ; Sarit SHARMA ; Amarender Singh PURI ; Bhabhadev GOSWAMI ; Devendra DESAI ; C. Ganesh PAI ; Kiran PEDDI ; Mathew PHILIP ; Rakesh KOCHHAR ; Sandeep NIJHAWAN ; Shobna BHATIA ; N. Sridhara RAO
Intestinal Research 2021;19(2):206-216
Background/Aims:
The national registry for inflammatory bowel disease (IBD) was designed to study epidemiology and prescribing pattern of treatment of IBD in India.
Methods:
A multicenter, cross-sectional, prospective registry was established across four geographical zones of India. Adult patients with ulcerative colitis (UC) or Crohn’s disease (CD) were enrolled between January 2014 and December 2015. Information related to demographics; disease features; complications; and treatment history were collected and analyzed.
Results:
A total of 3,863 patients (mean age, 36.7 ± 13.6 years; 3,232 UC [83.7%] and 631 CD [16.3%]) were enrolled. The majority of patients with UC (n = 1,870, 57.9%) were from north, CD was more common in south (n = 348, 55.5%). The UC:CD ratio was 5.1:1. There was a male predominance (male:female = 1.6:1). The commonest presentation of UC was moderately severe (n = 1,939, 60%) and E2 disease (n = 1,895, 58.6%). Patients with CD most commonly presented with ileocolonic (n = 229, 36.3%) inflammatory (n = 504, 79.9%) disease. Extraintestinal manifestations were recorded among 13% and 20% of patients in UC and CD respectively. Less than 1% patients from both cohorts developed colon cancer (n = 26, 0.7%). The commonly used drugs were 5-aminosalicylates (99%) in both UC and CD followed by azathioprine (34.4%). Biologics were used in only 1.5% of patients; more commonly for UC in north and CD in south.
Conclusions
The national IBD registry brings out diversities in the 4 geographical zones of India. This will help in aiding research on IBD and improving quality of patient care.
3.Colitis and Crohn’s Foundation (India): a first nationwide inflammatory bowel disease registry
Ajit SOOD ; Kirandeep KAUR ; Ramit MAHAJAN ; Vandana MIDHA ; Arshdeep SINGH ; Sarit SHARMA ; Amarender Singh PURI ; Bhabhadev GOSWAMI ; Devendra DESAI ; C. Ganesh PAI ; Kiran PEDDI ; Mathew PHILIP ; Rakesh KOCHHAR ; Sandeep NIJHAWAN ; Shobna BHATIA ; N. Sridhara RAO
Intestinal Research 2021;19(2):206-216
Background/Aims:
The national registry for inflammatory bowel disease (IBD) was designed to study epidemiology and prescribing pattern of treatment of IBD in India.
Methods:
A multicenter, cross-sectional, prospective registry was established across four geographical zones of India. Adult patients with ulcerative colitis (UC) or Crohn’s disease (CD) were enrolled between January 2014 and December 2015. Information related to demographics; disease features; complications; and treatment history were collected and analyzed.
Results:
A total of 3,863 patients (mean age, 36.7 ± 13.6 years; 3,232 UC [83.7%] and 631 CD [16.3%]) were enrolled. The majority of patients with UC (n = 1,870, 57.9%) were from north, CD was more common in south (n = 348, 55.5%). The UC:CD ratio was 5.1:1. There was a male predominance (male:female = 1.6:1). The commonest presentation of UC was moderately severe (n = 1,939, 60%) and E2 disease (n = 1,895, 58.6%). Patients with CD most commonly presented with ileocolonic (n = 229, 36.3%) inflammatory (n = 504, 79.9%) disease. Extraintestinal manifestations were recorded among 13% and 20% of patients in UC and CD respectively. Less than 1% patients from both cohorts developed colon cancer (n = 26, 0.7%). The commonly used drugs were 5-aminosalicylates (99%) in both UC and CD followed by azathioprine (34.4%). Biologics were used in only 1.5% of patients; more commonly for UC in north and CD in south.
Conclusions
The national IBD registry brings out diversities in the 4 geographical zones of India. This will help in aiding research on IBD and improving quality of patient care.
4.Use of thiopurines in inflammatory bowel disease: an update
Arshdeep SINGH ; Ramit MAHAJAN ; Saurabh KEDIA ; Amit Kumar DUTTA ; Abhinav ANAND ; Charles N. BERNSTEIN ; Devendra DESAI ; C. Ganesh PAI ; Govind MAKHARIA ; Harsh Vardhan TEVETHIA ; Joyce WY MAK ; Kirandeep KAUR ; Kiran PEDDI ; Mukesh Kumar RANJAN ; Perttu ARKKILA ; Rakesh KOCHHAR ; Rupa BANERJEE ; Saroj Kant SINHA ; Siew Chien NG ; Stephen HANAUER ; Suhang VERMA ; Usha DUTTA ; Vandana MIDHA ; Varun MEHTA ; Vineet AHUJA ; Ajit SOOD
Intestinal Research 2022;20(1):11-30
Inflammatory bowel disease (IBD), once considered a disease of the Western hemisphere, has emerged as a global disease. As the disease prevalence is on a steady rise, management of IBD has come under the spotlight. 5-Aminosalicylates, corticosteroids, immunosuppressive agents and biologics are the backbone of treatment of IBD. With the advent of biologics and small molecules, the need for surgery and hospitalization has decreased. However, economic viability and acceptability is an important determinant of local prescription patterns. Nearly one-third of the patients in West receive biologics as the first/initial therapy. The scenario is different in developing countries where biologics are used only in a small proportion of patients with IBD. Increased risk of reactivation of tuberculosis and high cost of the therapy are limitations to their use. Thiopurines hence become critical for optimal management of patients with IBD in these regions. However, approximately one-third of patients are intolerant or develop adverse effects with their use. This has led to suboptimal use of thiopurines in clinical practice. This review article discusses the clinical aspects of thiopurine use in patients with IBD with the aim of optimizing their use to full therapeutic potential.